Praxis stops EMBOLD study early after relutrigine shows efficacy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Praxis Precision Medicines Inc. (PRAX) PT Raised to $500 at Truist Securities
December 8, 2025 6:26 AM ESTTruist Securities analyst Joon Lee raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $500.00 (from $360.00) while maintaining a Buy rating.
The analyst comments "Vormatrigine reported 100% median seizure reduction at week 8, which was sustained through wk 16 in full Ph2 RADIANT. The results... More
